Search

Your search keyword '"Shiffman M"' showing total 416 results
Start Over Author "Shiffman M" Language english
416 results on '"Shiffman M"'

1. HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

Author

Sarrazin C, Castelli F, Andreone P, Buti M, Colombo M, Pol S, Calinas F, Puoti M, Olveira A, Shiffman M, Stern JO, Kukolj G, Roehrle M, Aslanyan S, Deng Q, Vinisko R, Mensa FJ, and Nelson DR

Subjects
Chronic hepatitis C, NS3 protease inhibitor, non-nucleoside polymerase inhibitor, cirrhosis, antiviral, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Christoph Sarrazin,1 Francesco Castelli,2 Pietro Andreone,3 Maria Buti,4 Massimo Colombo,5 Stanislas Pol,6 Filipe Calinas,7 Massimo Puoti,8 Antonio Olveira,9 Mitchell Shiffman,10 Jerry O Stern,11 George Kukolj,12 Michael Roehrle,13 Stella Aslanyan,11 Qiqi Deng,11 Richard Vinisko,11 Federico J Mensa,11 David R Nelson,14 on behalf of the HCVerso1 and 2 study groups 1Department of Internal Medicine 1, JW Goethe University Hospital, Frankfurt, Germany; 2Department of Infectious and Tropical Diseases, University of Brescia, Brescia, 3Department of Medical and Surgical Sciences, Università di Bologna and Azienda Ospedaliero-Universitaria, Policlinico Sant‘Orsola-Malpighi, Bologna, Italy; 4Department of Internal Medicine, Hospital Universitari Vall d’Hebron and CIBERehd del Instituto Carlos III, Barcelona, Spain; 5Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy; 6University Paris Descartes, Department of Hepatology, Hospital Cochin, APHP and INSERM UMS-20, Institut Pasteur, Paris, France; 7Department of Gastroenterology, Centro Hospitalar de Lisboa Central, Lisbon, Portugal; 8Department of Infectious Diseases, AO Ospedale Niguarda Cà Granda, Milan, Italy; 9Liver Unit, Hospital Universitario La Paz, CIBERehd, Madrid, Spain; 10Liver Institute of Virginia, Bon Secours Health System, Richmond, VA, USA; 11Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 12Boehringer Ingelheim Ltd/Ltée, Burlington, ON, Canada; 13Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 14Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA Abstract: The interferon-free combination of once-daily faldaprevir 120 mg, twice-daily deleobuvir 600 mg, and weight-based ribavirin was evaluated in two Phase III studies (HCVerso1, HCVerso2) in hepatitis C virus genotype-1b-infected, treatment-naïve patients, including those ineligible for peginterferon (HCVerso2). Patients without cirrhosis were randomized to 16 weeks (Arm 1; n=208 HCVerso1, n=213 HCVerso2) or 24 weeks (Arm 2; n=211 in both studies) of faldaprevir + deleobuvir + ribavirin. Patients with compensated cirrhosis received open-label faldaprevir + deleobuvir + ribavirin for 24 weeks (Arm 3; n=51, n=72). Primary endpoints were comparisons of adjusted sustained virologic response (SVR) rates with historical rates: 71% (HCVerso1) and 68% (HCVerso2). Adjusted SVR12 rates were significantly greater than historical controls for Arms 1 and 2 in HCVerso2 (76%, 95% confidence interval [CI] 71–81, P=0.002; 81%, 95% CI 76–86, P

Published
2016

2. Mammograms in cosmetic breast surgery

Author

Shiffman M

Subjects
Mammograms, Cosmetic Surgery, Breast, Surgery, RD1-811
Abstract

Mammograms are necessary as preoperative preparation for breast surgery in certain patients. There is a definite need for mammograms preoperatively in patients over 40 who should be obtaining mammograms on an annual basis. Under the age of 40 mammograms are up to the discretion of the surgeon. Postoperative mammograms should be obtained as a baseline 6-12 months after breast surgery.

Published
2005

3. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

Author

Abdelmalek, M., Bhamidimarri, K., Borg, B., Caldwell, S., Fenkel, J., Freilich, B., Fuchs, M., Ghabril, M., Ghalib, R., Gonzalez, S., Gordon, S., Hameed, B., Harrison, S., Kayali, Z., Kemmer, N., Korenblat, K., Lai, M., Landis, C., Lawitz, E., Lee, W., Lidofsky, S., Mena, E., Noureddin, M., Paredes, A., Pyrsopoulos, N., Reddy, R., Rinella, M., Rockey, D., Rodriguez, M., Ryan, M., Sarkar, S., Satapathy, S., Scanga, A., Shiffman, M., Siddiqui, M., Simonetto, D., Syn, W., Thuluvath, P., Vemulapalli, R., Vierling, J., Younes, Z., Albillos, A., Ruiz-Tapiador, J. Arenas, Augustin, S., Calleja, J., Garcia, J. Crespo, Buey, L. Garcia, Garcia-Pagan, J.C., Villanueva, C., Bureau, C., Carbonell, N., Leroy, V., Rautou, P.-E., Heinzow, H., Schiefke, I., Zipprich, A., Berzigotti, A., Muellhaupt, B., Garcia-Tsao, Guadalupe, Bosch, Jaime, Kayali, Zeid, Harrison, Stephen A., Abdelmalek, Manal F., Lawitz, Eric, Satapathy, Sanjaya K., Ghabril, Marwan, Shiffman, Mitchell L., Younes, Ziad H., Thuluvath, Paul J., Berzigotti, Annalisa, Albillos, Agustin, Robinson, James M., Hagerty, David T., Chan, Jean L., and Sanyal, Arun J.

Published
2020
Full Text
View/download PDF

8. Contributions to the Theory of Games (AM-28), Volume II

Author

ARROW, K. J., BARANKIN, E. W., BLACKWELL, D., BOTT, R., DALKEY, N., DRESHER, M., GALE, D., GILLIES, D. B., GLICKSBERG, I., GROSS, O., KARLIN, S., KUHN, H. W., MAYBERRY, J. P., MILNOR, J. W., MOTZKIN, T. S., VON NEUMANN, J., RAIFFA, H., SHAPLEY, L. S., SHIFFMAN, M., STEWART, F. M., THOMPSON, G. L., THRALL, R. M., Kuhn, H. W., Tucker, A. W., ARROW, K. J., BARANKIN, E. W., BLACKWELL, D., BOTT, R., DALKEY, N., DRESHER, M., GALE, D., GILLIES, D. B., GLICKSBERG, I., GROSS, O., KARLIN, S., KUHN, H. W., MAYBERRY, J. P., MILNOR, J. W., MOTZKIN, T. S., VON NEUMANN, J., RAIFFA, H., SHAPLEY, L. S., SHIFFMAN, M., STEWART, F. M., THOMPSON, G. L., THRALL, R. M., Kuhn, H. W., and Tucker, A. W.

Published
2016
Full Text
View/download PDF

11. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

Author

Manns, M. P., Pockros, P. J., Norkrans, G., Smith, C. I., Morgan, T. R., Häussinger, D., Shiffman, M. L., Hadziyannis, S. J., Schmidt, W. N., Jacobson, I. M., Bárcena, R., Schiff, E. R., Shaikh, O. S., Bacon, B., Marcellin, P., Deng, W., Esteban-Mur, R., Poynard, T., Pedicone, L. D., Brass, C. A., Albrecht, J. K., and Gordon, S. C.

Published
2013
Full Text
View/download PDF

34. Negative-Pressure Wound Therapy as Prevention Measure After Cardiac Surgery: Principles and Techniques

Author

Valen, Richard, Domingues, Carina, Bogers, Ad, Shiffman, M., Low, M., and Cardiothoracic Surgery

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Treatment duration, Psychological intervention, Surgical wound, Cardiac surgery, Intervention (counseling), Negative-pressure wound therapy, Perioperative care, Medicine, business, Intensive care medicine, Surgical site infection
Abstract

Reduction of surgical site infection (SSI) rates after (cardiac) surgery remains an important topic for all involved in the surgical domain. These infections lead to a higher risk for mortality and an increased morbidity in the individual patient. Despite many advances in perioperative care, however, the percentage of SSI has not declined. On a macrolevel, the costs associated with SSI are enormous, and all possible interventions to reduce SSI should be investigated. A possible new intervention is negative topical pressure therapy on clean, closed surgical wounds. In this chapter the theory behind this technique is explored, advice on patient selection is given, and treatment duration is discussed.

Published
2018

35. P254 Development of a primary palliative care model that includes a novel approach to address the needs of caregivers of adults with cystic fibrosis - improving life with cystic fibrosis: a primary palliative care partnership

Author

Georgiopoulos, A.M., Glajchen, M., Markovitz, M., Portenoy, R., DiFiglia, S., Wang, J., Walker, P., Shiffman, M., Pollinger, S., Middour-Oxler, B., Linnemann, R.W., Kier, C., Hardcastle, M., Hadjiliadis, D., Friedman, D., Fischer, F., Berdella, M., Basile, M., Abdullah, R., Yonker, L., and Dhingra, L.

Published
2021
Full Text
View/download PDF

38. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

Author

Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D, ELEVATE Study Group […, Akram J, Bessonova E, Bilodeau M, Bloomer J, Botta Fridlund D, Bzowej N, Calmus Y, Carbonell N, Caro Patón A, Cholewinska G, Chuang WL, Colombato L, Colombo M, Craxi A, Di Leo A, Diago M, Dumortier J, Elkasahab M, Everson G, Fallon M, Fedeli G, Finazzi R, Fontanella A, Francavilla A, Gadano A, Gambarin Gelwan M, Gordon F, Graus Morales J, Grieco A, Gugenheim J, Homenda W, Iaquinto G, Kang H, Khan Z, Kuliczkowski K, Kwo P, Lee JH, Lee W, Lee YS, Mazur W, Moreno C, Morozov V, Muñoz A, Navasa Anadón M, Nijhawan S, Pinzello G, Poordad F, Prieto Castillo M, Rafalsky V, Rapaccini G, Regenstein F, Rewak W, Riley T, Ripoll Noiseux C, Rizzetto M, Rodrigo Lopez J, Russo M, Samuel D, Sánchez Antolín G, Satyanaryana R, Savarino V, Shiffman M, Sigal S, Solá Lamoglia R, Sterling R, Tanno H, Te H, Terg R, Thuluvath P, Trepo C, Vargas H, Xiol Quingles X, Zaman A, Fontana R, Kim K, Abrams C, Gish R, Cardenas A, ANDREONE, PIETRO, MAZZELLA, GIUSEPPE, Afdhal, NH, Giannini, EG, Tayyab, G, Mohsin, A, Lee, JW, Andriulli, A, Jeffers, L, McHutchison, J, Chen, PJ, Han, KH, Campbell, F, Hyde, D, Brainsky, A, Theodore, D, Craxi, A, Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D, ELEVATE Study Group […, Akram J, Andreone P, Bessonova E, Bilodeau M, Bloomer J, Botta-Fridlund D, Bzowej N, Calmus Y, Carbonell N, Caro Patón A, Cholewinska G, Chuang WL, Colombato L, Colombo M, Craxi A, Di Leo A, Diago M, Dumortier J, Elkasahab M, Everson G, Fallon M, Fedeli G, Finazzi R, Fontanella A, Francavilla A, Gadano A, Gambarin-Gelwan M, Gordon F, Graus Morales J, Grieco A, Gugenheim J, Homenda W, Iaquinto G, Kang H, Khan Z, Kuliczkowski K, Kwo P, Lee JH, Lee W, Lee YS, Mazur W, Mazzella G, Moreno C, Morozov V, Muñoz A, Navasa Anadón M, Nijhawan S, Pinzello G, Poordad F, Prieto Castillo M, Rafalsky V, Rapaccini G, Regenstein F, Rewak W, Riley T, Ripoll Noiseux C, Rizzetto M, Rodrigo Lopez J, Russo M, Samuel D, Sánchez Antolín G, Satyanaryana R, Savarino V, Shiffman M, Sigal S, Solá Lamoglia R, Sterling R, Tanno H, Te H, Terg R, Thuluvath P, Trepo C, Vargas H, Xiol Quingles X, Zaman A, Fontana R, Kim K, Abrams C, Gish R, Cardenas A, and …]

Subjects
Liver Cirrhosis, Male, Cirrhosis, Chronic liver disease, Benzoates, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Receptors, Clinical endpoint, 80 and over, Medicine, CIRRHOSIS, Aged, 80 and over, Benzoic Acids, General Medicine, CHRONIC LIVER DISEASE, Middle Aged, Hydrazines, Thrombopoietin, Elective Surgical Procedures, Anesthesia, Female, Elective Surgical Procedure, Receptors, Thrombopoietin, Adult, Adolescent, Eltrombopag, ELTROMBOPAG, Hemorrhage, Platelet Transfusion, Placebo, Young Adult, Double-Blind Method, Elective, Surgical Procedures, Elective, Humans, Aged, THROMBOCYTOPENIA, Surgical Procedures, business.industry, Platelet Count, cirrhosis, Settore MED/09 - MEDICINA INTERNA, medicine.disease, Thrombocytopenia, Platelet transfusion, chemistry, Chronic Disease, Pyrazoles, business
Abstract

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7 days after the procedure. A key secondary end point was the occurrence of bleeding (World Health Organization [WHO] grade 2 or higher) during this period.A platelet transfusion was avoided in 104 of 145 patients who received eltrombopag (72%) and in 28 of 147 who received placebo (19%) (P0.001). No significant difference between the eltrombopag and placebo groups was observed in bleeding episodes of WHO grade 2 or higher, which were reported in 17% and 23% of patients, respectively. Thrombotic events of the portal venous system were observed in 6 patients who received eltrombopag, as compared with 1 who received placebo, resulting in the early termination of the study. The incidence and severity of other adverse events were similar in the eltrombopag and placebo groups.Eltrombopag reduced the need for platelet transfusions in patients with chronic liver disease who were undergoing elective invasive procedures, but it was associated with an increased incidence of portal-vein thrombosis, as compared with placebo. (Funded by GlaxoSmithKline; ELEVATE ClinicalTrials.gov number, NCT00678587.).

Published
2012

40. Contributions to the Theory of Riemann Surfaces. (AM-30)

Author

AHLFORS, L. V., BERGMAN, S., BERS, L., BOCHNER, S., CALABI, E., FOURFÈS, L., HEINS, M., JENKINS, J. A., KAKUTANI, S., KAPLAN, W., KODAIRA, K., MORSE, M., NEHARI, Z., ROSENBLOOM, P. C., ROYDEN, H. L., SARIO, L., SCHAEFFER, A. C., SCHIFFER, M., SHIFFMAN, M., SPENCER, D. C., WARSCHAWSKI, S. E., Ahlfors, L., Calabi, E., Morse, M., Sario, L., Spencer, D., AHLFORS, L. V., BERGMAN, S., BERS, L., BOCHNER, S., CALABI, E., FOURFÈS, L., HEINS, M., JENKINS, J. A., KAKUTANI, S., KAPLAN, W., KODAIRA, K., MORSE, M., NEHARI, Z., ROSENBLOOM, P. C., ROYDEN, H. L., SARIO, L., SCHAEFFER, A. C., SCHIFFER, M., SHIFFMAN, M., SPENCER, D. C., WARSCHAWSKI, S. E., Ahlfors, L., Calabi, E., Morse, M., Sario, L., and Spencer, D.

Published
1953
Full Text
View/download PDF

41. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

Author

Schiff E., Lai C. -L., Hadziyannis S., Nuehaus P., Terrault N., Colombo M., Tillmann H., Samuel D., Zuezem S., Villenueve J. -P., Arteburn S., Borroto-Esoda K., Brosgart C., Chuck S., Shakil A. O., Fung J., Alberti A., Lok A., Picciotto A., Torre F., Riely C., Trepo C., Bizollon T., Bottaa-Fridlund D., Gerolami R., Douglas D., Ranjan D., Faust D., Trojan J., Gane E., Villa E., Boarino M., Sokal E., Starkel P., Bonino F., Maurizio B., Gordon F., Pratt J., Berr F., Schiefke I., McCaughan G., Strasser S., Dusheiko G., Pageaux G. P., Larrey D., Pastore G., Santantonio T., Alexander G., Woodall T., Van Vlierberghe H., Colle I., Harley H., Guggenheim J., Myx-Staccini A., Metreau J. M., Mavier P., Vierling J., Tran T., Girgrah N., Nyberg L., Yuen M. -F., Ma M., Balnco M. D., Merli M., Tanzilli P., Angelico M., Di Paolo D., Rizzetto M., Marzano A., Lampertico P., Prieto M., Berenguer M., Felder M., Sterneck M., Willems M., Charlton M., Gunneson T., Ritter M., Voight M., Swift J., Shiffman M., Tassopoulos N., Klissas I., Naourmov N., Chamouard P., Marcellin P., Durand F., Angus P., Nathan C., Toniutto P., Fumo E., Andreone P., Cursaro C., Barcena R., Hoz F. G., Zachoval R., Christina M., De Man R. A., Metselaar H., Fagiuoli S., Schiff, E, Lai, C, Hadziyannis, S, Nuehaus, P, Terrault, N, Colombo, M, Tillmann, H, Samuel, D, Zuezem, S, Villenueve, J, Arteburn, S, Borroto-Esoda, K, Brosgart, C, Chuck, S, Shakil, A, Fung, J, Alberti, A, Lok, A, Picciotto, A, Torre, F, Riely, C, Trepo, C, Bizollon, T, Bottaa-Fridlund, D, Gerolami, R, Douglas, D, Ranjan, D, Faust, D, Trojan, J, Gane, E, Villa, E, Boarino, M, Sokal, E, Starkel, P, Bonino, F, Maurizio, B, Gordon, F, Pratt, J, Berr, F, Schiefke, I, Mccaughan, G, Strasser, S, Dusheiko, G, Pageaux, G, Larrey, D, Pastore, G, Santantonio, T, Alexander, G, Woodall, T, Van Vlierberghe, H, Colle, I, Harley, H, Guggenheim, J, Myx-Staccini, A, Metreau, J, Mavier, P, Vierling, J, Tran, T, Girgrah, N, Nyberg, L, Yuen, M, Ma, M, Balnco, M, Merli, M, Tanzilli, P, Angelico, M, Di Paolo, D, Rizzetto, M, Marzano, A, Lampertico, P, Prieto, M, Berenguer, M, Felder, M, Sterneck, M, Willems, M, Charlton, M, Gunneson, T, Ritter, M, Voight, M, Swift, J, Shiffman, M, Tassopoulos, N, Klissas, I, Naourmov, N, Chamouard, P, Marcellin, P, Durand, F, Angus, P, Nathan, C, Toniutto, P, Fumo, E, Andreone, P, Cursaro, C, Barcena, R, Hoz, F, Zachoval, R, Christina, M, De Man, R, Metselaar, H, and Fagiuoli, S

Subjects
Male, medicine.medical_treatment, Liver transplantation, medicine.disease_cause, Gastroenterology, lamivudine-resistant, chemistry.chemical_compound, antiviral therapy, Secondary Prevention, Adefovir, Prospective Studies, Adefovir dipivoxil, medicine.diagnostic_test, liver transplantation, Lamivudine, Middle Aged, Hepatitis B, Drug Therapy, Combination, Female, Kidney Diseases, medicine.drug, Adult, medicine.medical_specialty, Waiting Lists, Adenine, Antiviral Agents, DNA, Viral, Drug Resistance, Viral, Hepatitis B virus, Humans, Liver Transplantation, Organophosphonates, Bilirubin, Internal medicine, medicine, wait-listed, hepatitis B virus, Prothrombin time, Transplantation, Hepatology, business.industry, medicine.disease, chemistry, Immunology, Surgery, hepatitis B, business
Abstract

Wait-listed (n = 226) or post-liver transplantation (n = 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable (

Published
2007

48. LBP-002 - Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study

Author

Hirschfield, G., Boudes, P., Bowlus, C., Gitlin, N., Michael, G., Harrison, S., Gordon, S.C., Aspinall, R., Doerffel, Y., Kremer, A.E., Sheridan, D., Bacon, B., Berg, C., Borg, B., Hassanein, T., Odin, J., Shiffman, M., Thuluvath, P.J., Thorburn, D., Bernstein, D., Buggisch, P., Corless, L., Levy, C., Mayo, M.J., Swain, M.G., Vierling, J., Wörns, M.-A., Steinberg, A.(S.), Bergheanu, S., Choi, Y.-J., Varga, M., Martin, R., Mcwherter, C., and Jones, D.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results